Skip to content
Search

Latest Stories

Epilepsy treatment: England to roll out new laser beam surgery next month

Epilepsy treatment: England to roll out new laser beam surgery next month

This new epilepsy treatment targets the part of the brain causing seizures without the need for invasive surgery 

Good news for patients whose epilepsy cannot be controlled by standard anti-seizure drugs! Next month, NHS England will introduce a cutting-edge laser beam therapy that can prevent seizures in these individuals.

Known as Laser Interstitial Thermal Therapy (LITT), the advanced treatment targets the part of the brain causing seizures without the need for invasive surgery, the health service said.


The new fibre optic laser therapy is being offered at King’s College Hospital in London and The Walton Centre in Liverpool. Starting from June, it will be gradually extended to eligible patients across England.

Each year, it is expected to benefit up to 50 epilepsy patients in England who are resistant to standard anti-seizure medications.

“This groundbreaking new treatment will change the lives of those with severe epilepsy improving quality of life and providing much-needed assurance,” said Andrew Stephenson, Minister of State for Health.

James Palmer, NHS England’s Medical Director for Specialised Services and a Consultant Neurosurgeon, noted that it will offer new hope to patients for whom standard drugs are not effective in controlling their seizures.

“Not only will this world-leading technology help replace invasive surgery for patients, which can have a huge impact and take months to recover from, it will also allow clinicians to better target the parts of the brain causing the epilepsy, which dramatically reduces the risks and helps cut patients’ recovery time both in and out of hospital,” he added.

Laura Diable, 39, from Birkenhead, shared that she had not had one seizure since having the procedure nearly a year ago. She was one of the first three patients to have LITT at The Walton Centre.

“Before, the seizures were incapacitating me, leaving black spots in my memory. Thanks to LITT I’ve been able to get on with my life and worry less about my epilepsy – I can’t thank the team at The Walton Centre enough,” she said.

It is estimated that around 600,000 people are currently living with Epilepsy across the UK.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less